DCP2 Antibody (C-Terminus)
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC-P, IF |
---|---|
Primary Accession | Q8IU60 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 48kDa |
Dilution | IHC-P (5 µg/ml), WB (1-2 µg/ml), |
Gene ID | 167227 |
---|---|
Other Names | m7GpppN-mRNA hydrolase, 3.6.1.62, Nucleoside diphosphate-linked moiety X motif 20, Nudix motif 20, mRNA-decapping enzyme 2, hDpc, DCP2, NUDT20 |
Target/Specificity | Human DCP2. Multiple isoforms of DCP2 are known to exist. |
Reconstitution & Storage | Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles. |
Precautions | DCP2 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | DCP2 |
---|---|
Synonyms | NUDT20 |
Function | Decapping metalloenzyme that catalyzes the cleavage of the cap structure on mRNAs (PubMed:12417715, PubMed:12218187, PubMed:12923261, PubMed:21070968, PubMed:28002401, PubMed:31875550). Removes the 7-methyl guanine cap structure from mRNA molecules, yielding a 5'-phosphorylated mRNA fragment and 7m-GDP (PubMed:12486012, PubMed:12923261, PubMed:21070968, PubMed:28002401, PubMed:31875550). Necessary for the degradation of mRNAs, both in normal mRNA turnover and in nonsense-mediated mRNA decay (PubMed:14527413). Plays a role in replication-dependent histone mRNA degradation (PubMed:18172165). Has higher activity towards mRNAs that lack a poly(A) tail (PubMed:21070968). Has no activity towards a cap structure lacking an RNA moiety (PubMed:21070968). The presence of a N(6)-methyladenosine methylation at the second transcribed position of mRNAs (N(6),2'-O- dimethyladenosine cap; m6A(m)) provides resistance to DCP2-mediated decapping (PubMed:28002401). Blocks autophagy in nutrient-rich conditions by repressing the expression of ATG-related genes through degradation of their transcripts (PubMed:26098573). |
Cellular Location | Cytoplasm, P-body. Nucleus Note=Predominantly cytoplasmic, in processing bodies (PB) (PubMed:15273322). A minor amount is nuclear (PubMed:15273322) |
Tissue Location | Expressed in brain and testis. Not detected in heart (at protein level). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Decapping metalloenzyme that catalyzes the cleavage of the cap structure on mRNAs. Removes the 7-methyl guanine cap structure from mRNA molecules, yielding a 5'-phosphorylated mRNA fragment and 7m-GDP. Necessary for the degradation of mRNAs, both in normal mRNA turnover and in nonsense-mediated mRNA decay. Plays a role in replication-dependent histone mRNA degradation. Has higher activity towards mRNAs that lack a poly(A) tail. Has no activity towards a cap structure lacking an RNA moiety.
References
Lykke-Andersen J.,et al.Mol. Cell. Biol. 22:8114-8121(2002).
Wang Z.,et al.Proc. Natl. Acad. Sci. U.S.A. 99:12663-12668(2002).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Schmutz J.,et al.Nature 431:268-274(2004).
van Dijk E.,et al.EMBO J. 21:6915-6924(2002).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.